{
  "docId": "019de074-2806-77f1-979f-2c5838bae35a",
  "docSlug": "7e995254b839b7fbb7e998df4127a7b8",
  "documentTitle": "ATAI | Investor Presentation Deck | 33 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 33,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "traction",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 48,
  "notes": "Includes detailed TEAE (Treatment-emergent Adverse Event) breakdown by dose cohort.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-2806-77f1-979f-2c5838bae35a/23",
  "deckHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a",
  "deckJsonHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a.json",
  "deckAnchorHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.25,
        "x": 0.73,
        "y": 0.92
      },
      "kind": "callout",
      "text": "Preliminary data, subject to change",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16428700-6ceb-4bf6-88e7-95834f3ba0e3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.35,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "list",
      "text": "1. Well-tolerated up to 300mg. 2. No serious adverse events. 3. Comparable to placebo. 4. No significant sedation/benzodiazepine-like side effects.",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f9871902-dc89-4b09-9ad1-75d1094ab0a2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Note: TEAE = Treatment-emergent Adverse Event, SAD = Single Ascending Dose, MAD = Multiple Ascending Dose. 1-4 footnotes.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2776fd21-ea2d-4e32-a61c-b3d4f928be6c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.55,
        "x": 0.422,
        "y": 0.23
      },
      "kind": "table",
      "text": "GRX-917 Phase 1 MAD study safety data table",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0682643f-205b-4743-bfdb-429475c5bb91",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "GRX-917 Phase 1 data: no severe or serious adverse events, with minimal sedation or dizziness, confirms favourable safety profile",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8b89318e-fad3-4f93-85e9-f0dfdbf8637a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}